Similar articles

• More on pseudohypocalcemia and gadolinium-enhanced MRI.

  Prince MR, Choyke PL, Knopp MV. Prince MR, et al. N Engl J Med. 2004 Jan 1;350(1):87-8; author reply 87-8. doi: 10.1056/NEJM200401013500120. N Engl J Med. 2004. PMID: 14702437 No abstract available.
• Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis.

  Kefalas CH, Murray NG, Aguanno JJ, Dockery WD, Weinstein JS, Anderson K, Klintmalm GB. Kefalas CH, et al. Liver Transpl. 2004 Jan;10(1):136-40. doi: 10.1002/lt.20008. Liver Transpl. 2004. PMID: 14755791
• Gadodiamide administration causes spurious hypocalcemia.

  Prince MR, Erel HE, Lent RW, Blumenfeld J, Kent KC, Bush HL, Wang Y. Prince MR, et al. Radiology. 2003 Jun;227(3):639-46. doi: 10.1148/radiol.2273012007. Radiology. 2003. PMID: 12773671
• Safety of magnetic resonance imaging contrast agents.

  Shellock FG, Kanal E. Shellock FG, et al. J Magn Reson Imaging. 1999 Sep;10(3):477-84. doi: 10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e. J Magn Reson Imaging. 1999. PMID: 10508312 Review.
• Perfusion MRI: the five most frequently asked technical questions.

  Essig M, Shiroishi MS, Nguyen TB, Saake M, Provenzale JM, Enterline D, Anzalone N, Dörfler A, Rovira A, Wintermark M, Law M. Essig M, et al. AJR Am J Roentgenol. 2013 Jan;200(1):24-34. doi: 10.2214/AJR.12.9543. AJR Am J Roentgenol. 2013. PMID: 23255738 Free PMC article. Review.